Investors & Media
What’s new.


Press releases
Press releases.
Investor updates
Analyst reports
Analyst reports.
July 11th 2025
Jefferies - Efti/Pembro Looks Good vs. Other Combos and Other Therapies in NSCLC and HNSCC; Rated BUY, PT A$2.10 (Analyst: Dr David Stanton)
June 23rd 2025
Baird - Updated Phase 1 Safety/Efficacy HV Data for IMP761 (LAG-3) for Autoimmune; Rated OP, US$7 PT (Analyst: Colleen M. Kusy, CFA)
June 23rd 2025